Free Trial

Adial Pharmaceuticals (ADIL) Short Interest Ratio & Short Volume

Adial Pharmaceuticals logo
$0.65 -0.05 (-7.24%)
Closing price 04:00 PM Eastern
Extended Trading
$0.65 0.00 (-0.62%)
As of 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Adial Pharmaceuticals Short Interest Data

Adial Pharmaceuticals (ADIL) has a short interest of 549,400 shares, representing 8.50% of the float (the number of shares available for trading by the public). This marks a -19.83% decrease in short interest from the previous month. The short interest ratio (days to cover) is 0.7, indicating that it would take 0.7 days of the average trading volume of 1.61 million shares to cover all short positions.

Current Short Interest
549,400 shares
Previous Short Interest
685,300 shares
Change Vs. Previous Month
-19.83%
Dollar Volume Sold Short
$381,228.66
Short Interest Ratio
0.7 Days to Cover
Last Record Date
March 15, 2025
Outstanding Shares
6,575,000 shares
Float Size
6,460,000 shares
Short Percent of Float
8.50%
Today's Trading Volume
85,465 shares
Average Trading Volume
1,609,243 shares
Today's Volume Vs. Average
5%
Short Selling Adial Pharmaceuticals?
cover of A Guide to High-Short-Interest Stocks and How to Trade Them ebook

Sign up to receive the latest short interest report for Adial Pharmaceuticals and its competitors with MarketBeat's FREE newsletter.

Skip Charts & View Short Interest History

ADIL Short Interest Over Time

ADIL Days to Cover Over Time

ADIL Percentage of Float Shorted Over Time

Remove Ads

Adial Pharmaceuticals Short Interest History

Report DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date
3/15/2025549,400 shares $381,228.66 -19.8%8.5%0.7 $0.69
2/28/2025685,300 shares $537,960.50 +610.2%10.6%0.8 $0.79
2/15/202596,500 shares $71,525.80 +59.2%1.5%0.1 $0.74
1/31/202560,600 shares $50,298.00 +195.6%1.0%0.3 $0.83
1/15/202520,500 shares $20,910.00 -9.3%0.3%0.1 $1.02
12/31/202422,600 shares $22,826.00 -60.8%0.4%0.1 $1.01
12/15/202457,600 shares $62,784.00 +16.4%0.9%0.3 $1.09
11/30/202449,500 shares $49,500.00 -71.7%0.8%0.3 $1.00
11/15/2024175,000 shares $185,500.00 +121.8%2.8%1.2 $1.06
10/31/202478,900 shares $78,900.00 +54.1%1.3%0.6 $1.00
10/15/202451,200 shares $48,757.76 -34.2%0.8%0.2 $0.95
9/30/202477,800 shares $77,722.20 -47.0%1.2%0 $1.00
9/15/2024146,700 shares $158,436.00 -46.2%2.3%0.1 $1.08
8/31/2024272,800 shares $267,616.80 -14.5%4.3%0.1 $0.98
8/15/2024318,900 shares $309,045.99 +8.3%5.1%0.1 $0.97
7/31/2024294,400 shares $306,176.00 +92.5%7.2%0.1 $1.04
7/15/2024152,900 shares $169,719.00 -6.4%3.7%0.1 $1.11
6/30/2024163,300 shares $187,795.00 -25.2%4.0%0.1 $1.15
6/15/2024218,200 shares $285,842.00 +33.5%5.3%0.1 $1.31
5/31/2024163,400 shares $236,930.00 +23.5%4.0%0.1 $1.45
5/15/2024132,300 shares $187,866.00 -20.8%3.2%0 $1.42
4/30/2024167,100 shares $284,070.00 -83.5%4.4%0 $1.70
4/15/20241,010,000 shares $2.64 million +11,509.2%26.7%0.2 $2.61
3/31/20248,700 shares $11,571.00 -91.8%0.2%0 $1.33
3/15/2024105,600 shares $166,848.00 +275.8%7.0%0 $1.58
2/29/202428,100 shares $57,324.00 -83.8%1.9%0 $2.04
2/15/2024173,300 shares $201,028.00 +691.3%11.5%0.6 $1.16
1/31/202421,900 shares $24,968.19 -41.1%1.5%0.2 $1.14
1/15/202437,200 shares $53,984.64 +11.4%2.6%0.4 $1.45
12/31/202333,400 shares $62,124.00 +29.5%3.2%0.3 $1.86
12/15/202325,800 shares $45,150.00 -37.4%2.4%0.3 $1.75
11/30/202341,200 shares $90,228.00 -22.3%3.9%0.6 $2.19
11/15/202353,000 shares $112,360.00 -1.5%5.0%1.2 $2.12
10/31/202353,800 shares $103,834.00 +93.5%5.1%0.8 $1.93
10/15/202327,800 shares $77,006.00 -45.3%2.6%0.4 $2.77
9/30/202350,800 shares $141,218.92 +49.4%4.8%0.3 $2.78
9/15/202334,000 shares $99,620.00 -47.4%3.3%0.3 $2.93
8/31/202364,600 shares $282,948.00 -12.6%6.2%0.5 $4.38
8/15/202373,900 shares $283,916.41 +121.3%7.1%0.6 $3.84
7/31/202333,400 shares $268,035.00 -97.7%N/A0.3 $8.03
A brutally honest economic warning for 2025 (see proof) (Ad)

New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked side-by-side with figures like Warren Buffett, Alan Greenspan, Ron Paul, Jim Rickards, and Steve Forbes, to name but a few) says....

7/15/20231,430,000 shares $395,538.00 +3,084.9%N/A0.6 $0.28
6/30/202344,900 shares $9,348.18 -24.3%N/A0 $0.21
6/15/202359,300 shares $14,528.50 -36.4%N/A0.3 $0.25
5/31/202393,200 shares $24,511.60 -71.3%N/A0.3 $0.26
5/15/2023324,800 shares $104,812.96 -22.0%N/A0.5 $0.32
4/30/2023416,400 shares $143,449.80 +42.6%N/A0.6 $0.34
4/15/2023292,100 shares $87,045.80 -12.0%N/A0.4 $0.30
3/31/2023332,000 shares $116,200.00 -38.8%N/A0.5 $0.35
3/15/2023542,700 shares $201,884.40 +42.2%N/A0.8 $0.37
2/28/2023381,600 shares $167,904.00 +37.9%N/A0.6 $0.44
2/15/2023276,700 shares $102,655.70 +105.9%N/A1.1 $0.37
1/31/2023134,400 shares $63,168.00 -7.0%N/A0.6 $0.47
1/15/2023144,500 shares $46,254.45 +12.3%N/A1 $0.32
12/30/2022128,700 shares $27,670.50 -4.0%N/A1 $0.22
12/15/2022134,100 shares $32,572.89 +4.0%N/A1.4 $0.24
11/30/2022128,900 shares $34,789.98 -3.9%N/A1.3 $0.27
11/15/2022134,100 shares $39,438.81 -9.4%N/A0.9 $0.29
10/31/2022148,000 shares $43,660.00 -8.0%N/A0.9 $0.30
10/15/2022160,900 shares $52,614.30 -8.0%N/A0.6 $0.33
9/30/2022174,900 shares $61,215.00 -28.9%N/A0.3 $0.35
9/15/2022246,000 shares $119,777.40 -26.8%N/A0.3 $0.49
8/31/2022335,900 shares $180,311.12 +10.1%N/A0.4 $0.54
8/15/2022305,200 shares $181,594.00 -52.4%N/A0.4 $0.60
7/31/2022641,700 shares $417,105.00 -6.4%N/A0.9 $0.65
7/15/2022685,300 shares $1.12 million +17.9%N/A1.1 $1.63
6/30/2022581,500 shares $779,210.00 -27.4%N/A2.6 $1.34
6/15/2022801,200 shares $1.00 million -3.0%N/A4.7 $1.25
5/31/2022825,800 shares $1.04 million -4.8%N/A6.2 $1.26
5/15/2022867,100 shares $1.11 million +0.8%N/A7.6 $1.28
4/30/2022860,300 shares $1.21 million -8.3%N/A7.4 $1.41
4/15/2022938,000 shares $1.64 million +10.5%N/A7.8 $1.75
3/31/2022849,100 shares $1.71 million -2.1%N/A7.3 $2.01
3/15/2022867,000 shares $1.59 million +5.9%N/A7.4 $1.83
2/28/2022818,500 shares $1.69 million +8.3%N/A6.7 $2.06
2/15/2022755,600 shares $1.65 million +2.2%N/A5.1 $2.18
1/31/2022739,700 shares $1.54 million -9.0%4.3%4.3 $2.08
1/15/2022812,600 shares $2.13 million -5.7%4.7%4.1 $2.62
12/31/2021861,500 shares $2.33 million +1.1%5.0%3.8 $2.70
12/15/2021852,100 shares $2.29 million -9.5%4.9%3.1 $2.69
11/30/2021941,200 shares $2.62 million -5.5%5.6%3 $2.78
11/15/2021995,700 shares $3.15 million +13.7%5.9%2.6 $3.16
10/29/2021875,600 shares $2.81 million -11.0%5.3%1.9 $3.21
10/15/2021984,100 shares $3.82 million +3.4%6.0%2.1 $3.88
9/30/2021951,400 shares $4.08 million +10.3%5.8%1.6 $4.29
9/15/2021862,500 shares $3.54 million -3.0%5.3%1 $4.10
8/31/2021888,900 shares $3.64 million -10.0%5.6%0.7 $4.10
8/13/2021987,800 shares $3.24 million -9.4%6.0%0.8 $3.28
7/30/20211,090,000 shares $2.66 million +16.9%6.2%0.9 $2.44
7/15/2021932,600 shares $2.32 million -24.8%5.8%0.8 $2.49
6/30/20211,240,000 shares $3.16 million +103.0%7.9%1.2 $2.55
A brutally honest economic warning for 2025 (see proof) (Ad)

New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked side-by-side with figures like Warren Buffett, Alan Greenspan, Ron Paul, Jim Rickards, and Steve Forbes, to name but a few) says....

6/15/2021611,000 shares $1.65 million -13.4%3.9%0.8 $2.70
5/28/2021705,700 shares $1.74 million +11.4%4.6%2.9 $2.47
5/14/2021633,500 shares $1.30 million -4.2%N/A1.8 $2.05
4/30/2021661,100 shares $1.44 million -9.7%N/A1.4 $2.17
4/15/2021731,900 shares $1.69 million +16.5%N/A1.2 $2.31
3/31/2021628,000 shares $1.44 million +14.8%N/A0.9 $2.30
3/15/2021547,200 shares $1.41 million +8.2%N/A0.8 $2.57
2/26/2021505,700 shares $1.39 million +7.6%N/A0.8 $2.75
2/12/2021469,800 shares $1.37 million +35.8%N/A0.7 $2.91
1/29/2021346,000 shares $743,900.00 -6.4%N/A0.6 $2.15
1/15/2021369,800 shares $761,788.00 +16.2%N/A0.7 $2.06
12/31/2020318,300 shares $569,757.00 -5.7%N/A0.5 $1.79
12/15/2020337,400 shares $651,182.00 -7.2%N/A0.1 $1.93
11/30/2020363,700 shares $709,215.00 -14.5%N/A0.1 $1.95
11/15/2020425,600 shares $783,104.00 -32.8%N/A0.2 $1.84
10/30/2020633,000 shares $1.13 million +13.2%N/A0.3 $1.79
10/15/2020559,200 shares $1.08 million -9.2%N/A0.2 $1.94
9/30/2020615,500 shares $1.37 million +9.7%N/A0.2 $2.23
9/15/2020561,000 shares $746,130.00 +9.0%N/A0.7 $1.33
8/31/2020514,800 shares $710,424.00 +97.6%N/A0.5 $1.38
8/14/2020260,500 shares $403,775.00 -16.6%N/A0.3 $1.55
7/31/2020312,200 shares $502,642.00 +283.5%N/A0.3 $1.61
7/15/202081,400 shares $108,262.00 +40.8%N/A0.2 $1.33
6/30/202057,800 shares $79,764.00 +72.0%0.6%0.1 $1.38
6/15/202033,600 shares $52,080.00 +309.8%0.4%0.1 $1.55
5/29/20208,200 shares $13,448.00 +110.3%0.1%0 $1.64
5/15/20203,900 shares $5,304.00 -13.3%0.1%0 $1.36
4/30/20204,500 shares $6,673.95 -45.8%0.1%0 $1.48
4/15/20208,300 shares $10,958.49 -34.1%0.1%0.1 $1.32
3/31/202012,600 shares $17,514.00 -69.2%0.2%0.2 $1.39

ADIL Short Interest - Frequently Asked Questions

What is Adial Pharmaceuticals' current short interest?

Short interest is the volume of Adial Pharmaceuticals shares that have been sold short but have not yet been covered or closed out. As of March 15th, traders have sold 549,400 shares of ADIL short. 8.50% of Adial Pharmaceuticals' shares are currently sold short. Learn More on Adial Pharmaceuticals' current short interest.

What is a good short interest ratio for Adial Pharmaceuticals?

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. ADIL shares currently have a short interest ratio of 1.0. Learn More on Adial Pharmaceuticals's short interest ratio.

Which institutional investors are shorting Adial Pharmaceuticals?

As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Adial Pharmaceuticals: Concourse Financial Group Securities Inc.. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission.

What is a good short interest percentage for Adial Pharmaceuticals?

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 8.50% of Adial Pharmaceuticals' floating shares are currently sold short.

Is Adial Pharmaceuticals' short interest increasing or decreasing?

Adial Pharmaceuticals saw a decline in short interest in March. As of March 15th, there was short interest totaling 549,400 shares, a decline of 19.8% from the previous total of 685,300 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

What is Adial Pharmaceuticals' float size?

Adial Pharmaceuticals currently has issued a total of 6,575,000 shares. Some of Adial Pharmaceuticals' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Adial Pharmaceuticals currently has a public float of 6,460,000 shares.

How does Adial Pharmaceuticals' short interest compare to its competitors?

8.50% of Adial Pharmaceuticals' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Adial Pharmaceuticals: Lakeshore Biopharma Co., Ltd. (0.22%), Lipocine Inc. (1.60%), Mannatech, Incorporated (1.51%), Senti Biosciences, Inc. (0.35%), Cognition Therapeutics, Inc. (2.83%), IN8bio, Inc. (2.58%), NextCure, Inc. (0.30%), MIRA Pharmaceuticals, Inc. (7.97%), BioAtla, Inc. (9.86%), GlycoMimetics, Inc. (4.38%),

Which stocks are the most shorted right now?

As of the most recent reporting period, the following stocks had the largest short interest positions: Invesco QQQ ($26.28 billion), iShares 20+ Year Treasury Bond ETF ($9.53 billion), MicroStrategy Incorporated ($8.50 billion), Apollo Global Management, Inc. ($4.86 billion), Super Micro Computer, Inc. ($4.85 billion), Charter Communications, Inc. ($4.28 billion), Capital One Financial Co. ($4.08 billion), AppLovin Co. ($3.82 billion), Canadian Natural Resources Limited ($3.78 billion), and Schlumberger Limited ($2.87 billion). View all of the most shorted stocks.

What does it mean to sell short Adial Pharmaceuticals stock?

Short selling ADIL is an investing strategy that aims to generate trading profit from Adial Pharmaceuticals as its price is falling. ADIL shares are trading down $0.05 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

How does a short squeeze work against Adial Pharmaceuticals?

A short squeeze for Adial Pharmaceuticals occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of ADIL, which in turn drives the price of the stock up even further.

How often is Adial Pharmaceuticals' short interest reported?

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including ADIL, twice per month. The most recent reporting period available is March, 15 2025.




This page (NASDAQ:ADIL) was last updated on 3/27/2025 by MarketBeat.com Staff
From Our Partners